CA-KRAKEN
11.2.2021 15:32:09 CET | Business Wire | Press release
Kraken Digital Asset Exchange, one of the world’s largest cryptocurrency exchanges, today announced its backing of the newly launched Kraken Ventures, an independent investment fund targeting early stage companies and protocols across the crypto and fintech ecosystem. The fund will invest in the technologies powering the next wave of crypto and fintech innovation and provide entrepreneurs with the financial resources and industry expertise needed to build and scale their business.
Kraken Ventures will focus on areas including fintech, crypto companies & protocols, decentralized finance (DeFi) as well as enabling technologies such as AI, Machine and Deep Learning, Reg Tech, and cybersecurity. Kraken Ventures offers the best of both worlds in being a completely autonomous fund that’s backed by the resources and expertise of Kraken.
Led by a team with extensive experience in the crypto and financial services industry and leveraging its strategic partnership with Kraken, portfolio companies get access to the ideal environment for their teams to collaborate across the Kraken and broader fintech ecosystem. The fintech and crypto ecosystems will continue to be drawn closer together and Kraken Ventures will be investing at the intersection of these two dynamic industries.
Jesse Powell, co-founder and CEO of Kraken said: “As we enter the crypto industry’s next growth phase, Kraken Ventures will support entrepreneurs in making the financial system more open, inclusive, and transparent. With a strong team in place, Kraken Ventures offers the right combination of resources to bring the best ideas to their full potential. We’ve arrived at the point where crypto is starting to show its true potential, transforming the financial services industry and creating truly global, digital economies.”
Kraken Ventures will be led by Brandon Gath, who has 20 years of experience in the financial services and crypto industries. He most recently served as the Head of Corporate Development at Kraken and prior to joining Kraken helped lead CME Ventures, where he was an early investor in numerous unicorn startups across fintech, AI, Deep Learning, Quantum Computing and Crypto. He led early investments in Orbital Insight, Crosslend, Digital Currency Group, Nervana Systems, Crypto Facilities, Privitar, and Fortscale. Brandon has a wealth of professional experience ranging across venture capital, M&A, investing banking, and consulting. He holds an MBA from the University of Chicago in Entrepreneurial Finance.
Brandon Gath, General Partner of Kraken Ventures said: “Fintech and specifically crypto technology provides the opportunity to drastically change how businesses and consumers exchange and store value, invest, lend, borrow, and conduct global commerce. We take a long-term view on investing to add value from inception through each growth phase of our portfolio companies’ evolution. We will take a hands-on approach with our portfolio companies to provide guidance, new commercial opportunities and additional capital support. The possibility to leverage Kraken’s experience building a truly global, scalable platform enables us to support our portfolio companies from inception to market leadership. We’ve already identified some of the best opportunities out there and expect to announce our first investments in the near future.”
Brandon will be joined by Kirill Gourov and Akshi Federici . Kirill currently supports strategic investment for Kraken and previously managed blockchain investments for a New York-based multifamily office. Prior to this, he led blockchain strategy efforts at Expand Research, a subsidiary of The Boston Consulting Group. He has been actively involved in the Bitcoin community since early 2013 and has over 7 years of experience in the blockchain industry including investment, strategy development for both public and private chain applications, and business development for blockchain projects. Akshi Federici is a seasoned strategic operator with over 15 years of experience in the financial services and cryptocurrencies industries with The Boston Consulting Group, BlackRock, Conde Nast, ConsenSys, and Kraken.
For more information, please visit www.krakenventures.com
About Kraken
Based in San Francisco, Kraken is the world’s largest global digital asset exchange based on euro volume and liquidity. Kraken’s clients trade more than 50 digital assets and 7 different fiat currencies, including EUR, USD, CAD, GBP, JPY, CHF and AUD. Kraken was founded in 2011 and is the first digital asset exchange to have its market data displayed on the Bloomberg Terminal and one of the first to offer spot trading with margin, regulated derivatives and index services. Kraken is trusted by more than 5 million traders, institutions and authorities around the world.
Kraken is backed by investors including Hummingbird Ventures, Blockchain Capital and Digital Currency Group, among others. For more information about Kraken, please visit www.kraken.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005504/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom